First Online: 8 November 2018
Change Date: 22 November 2018
Change Type: Correction
Change Details: In the originally published version of this article, in Table 4, Ocrelizumab was incorrectly referred to as an anti-CD25 antibody. This has been corrected in the HTML and PDF versions of the article to an anti-CD20 antibody.
: M.F. is Editor-in-Chief of the <i>Journal of Neurology</i>, has received compensation for consulting services and/or speaking activities from Biogen Idec, Merck-Serono, Novartis and Teva and receives research support from ARiSLA (Fondazione Italiana di Ricerca per la SLA), Biogen Idec, Fondazione Italiana Sclerosi Multipla, the Italian Ministry of Health, Novartis, Roche and Teva. A.B.-O. has participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from Biogen Idec, Celgene/Receptos, GlaxoSmithKline, Medimmune, Merck/EMD Serono, Novartis, Roche/Genentech and Sanofi-Genzyme. F.P. has received unrestricted academic research grants from Biogen, Genzyme and Novartis, and on behalf of Frederik Piehl, his department has received travel support and/or compensation for lectures and/or participation in advisory boards from Biogen, Genzyme, Merck-Serono, Novartis, Roche and Teva, which have been exclusively used for the support of research activities. P.P. has received speakers honoraria from Biogen Idec, Excemed, Merck-Serono and Novartis. A.S. was a board member of Merck-Serono and Novartis and received speaker honoraria from Almirall, Excemed, Genzyme, Merck-Serono and Teva. S.V. has received consulting and lecturing fees, travel grants and research support from Biogen, Celgene, Genentech, Genzyme, MedDay, Merck-Serono, Novartis, Roche, Sanofi-Aventis and Teva. M.A.R. has received speakers honoraria from Biogen Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis and Teva and receives research support from the Fondazione Italiana Sclerosi Multipla and the Italian Ministry of Health.